On December 15, the Securities and Exchange Commission (SEC) proposed rule amendments regarding the availability of the Rule 10b5-1(c)(1) affirmative defense to insider trading liability and enhanced disclosure requirements....more
More than ever, life sciences companies are going public to raise capital for future growth. In fact, U.S. equity financing in life sciences skyrocketed to a record $7 billion in 2018—a 69 percent jump over the year...more
2/8/2019
/ Accounting Standards ,
Capital Formation ,
Capital Markets ,
Disclosure Requirements ,
Emerging Growth Companies ,
Initial Public Offering (IPO) ,
Internal Controls ,
Investment Banks ,
Life Sciences ,
Popular ,
Regulatory Standards ,
Reporting Requirements ,
Sarbanes-Oxley ,
Startups ,
Stock Exchange ,
Transparency